Latest advances in de-addiction strategies

Kathmandu University Medical Journal

Volumn 5, Issue 17, 2007, Pages 124-128

  Tamrakar, Sharad M ^a,c   Koirala, N R ^b  

^a Norvic Escorts International Hospital

^b TRIBHUVAN UNIVERSITY TEACHING HOSPITAL   (Nepal)

^c Norvic International Hospital   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CLONIDINE; FLUMAZENIL; LOFEXIDINE; METHADONE; MUSCLE RELAXANT AGENT; NALMEFENE; NALOXONE; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PSYCHOTROPIC AGENT;

ABSTINENCE; ADDICTION; ALCOHOLISM; BRAIN MAPPING; DETOXIFICATION; DRUG COST; GENETIC PREDISPOSITION; HABIT; HEALTH EDUCATION; HIGH RISK BEHAVIOR; HISTORY OF MEDICINE; HUMAN; NEUROBIOLOGY; REVIEW; RISK FACTOR; VENTRAL TEGMENTUM;

EID: 41949129125     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Nestler E. J. (2004) Historical review: Molecular and Cellular Mechanism of Opiate and Cocaine Addiction. In: Trends in Pharmacological Sciences, Vol. 25, Issue 4, pg 210-218.
2. Shrestha, N. M. (1997) Alcohol and Drug Problems. Kathmandu: Jeewan Support Printing Press.
3. Nahas G. G. & Burks T. F. (1997) Opiates and the brain. In: Drug Abuse in the Decade of the Brain. New York: IOS Press.
4. Lehrer A. (1999) Science-Based Views of Drug Addiction and its Treatment. Journal of American Medical Association, 282, 1314-1316.
5. Gelder, M., Mayou, R. & Cowen, P. (2001) Aetiological Models. In: Shorter Oxford Textbook of Psychiatry, pp 109-110, New York: Oxford University Press.
6. Cloninger, C. R. (1987) Neurogenic adaptive mechanisms in alcoholism. Science, 236, pp. 410-415.
7. Corbett AD, Henderson G, McKnight AT, Paterson SJ. (2006) 75 years of opioid research: the exciting but the vain quest for opioid research, British Journal of Pharmacology, 147, S153-S162.
8. Waisman Y, Marcus H, Ligumski M, Dinari G. (1991) Modulation by opiates of small intestinal prostaglandin E2 and 3′,5′cyclic adenosine monophosphate levels and of indomethacin-induced ulceration in the rat. Life Science, 48(21):2035-42.
9. Cucchia, A., Monnat, M., Spagnoli, J., Ferrero, F., & Bertschy, G. (1998). Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug and Alcohol Dependence, 52, 253-250.
10. Rabinowitz, J., Cohen, H., & Kotler, M. (1998). Outcomes of Ultra-rapid opiate detoxification combined with naltrexone maintenance and counselling. Psychiatric Services, 49, 831-833.
11. Albanese, A., Gevirtz, C., Oppenheim, B., Field, J., Abels, I., & Eustace, J. (2000).Outcome and six-month follow up of patients after ultra rapid opiate detoxification. Journal of Addictive Diseases, 19, 11-28.
12. O'Connor, P., & Kosten, T. (1998). Rapid and ultrarapid opioid detoxification techniques. JAMA, 279, 229-234.
13. Krabbe PF, Koning JP, Heinen N, Laheij RJ, van Cauter RM, Dejong CA (2003) Rapid detoxification from opioid dependence under general ansesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experience. Addiction Biology, 8(3), 351-8.
14. Gerra, M., Zaimovic, A., Rustichelli, M., Fontanesi, M., Zambelli, U., Timpano, M., Bocchi, C., & Delsignore, R. (2000). Rapid opiate detoxification in outpatient treatment. Relationship with naltrexone compliance. Journal of Substance Abuse Treatment, 18, 185-191.
15. Bell, J., Kimber, J., Lintjeris, N. (2001) Guidelines for rapid detoxification from opioids. Surry Hills: New South Wales Health Department.
16. London, M., Paul, E., & Gkolia, I. (2000). Ultra-rapid opiate detoxification in hosptial. Psychiatric Bulletin, 23, 544-46.
17. Bell, J., Young, M., Masterman, S., Morris, A., Mattick, R. P., & Bammer, G. (1999) A pilot study of naltrexone-accelerated detoxification in opioid dependence. Medical Journal of Australia, 171, 26-30.
18. Kienbaum, P., Heuter, T., Michel, M. C., Scherbaum, N., Gastpar, M., Peters, J. (2001) Chronic μ-Opioid Receptor Stimulation in Humans Decreases Muscle Sympathetic Nerve Activity. Circulation, 103:850.
19. Chugh, S. ( 2005) Latest Advances in De-addiction Strategies. New Delhi: International Institute for Deaddiction and Therapy (IIDRT) Brochure.
20. Carrew et al. (2003) Maintenance treatment with depot opioid antagonist in subcutaneous implants: an alternative in the treatment of opioid dependence. Addiction Biology, 8(4), 429-38.
21. Hulse GK, O'Neil G, Hatton M, Paech MJ (2003) Use of oral and implantable naltrexone in the management of the opioid impaired physician. Anaesthesia Intensive Care, 31(2), 196-201.
22. Corner SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW (2002) Depot Naltrexone: Long-lasting antagonism of effects on heroin in humans. Psychopharmacology (Berl), 159 (4), 351-60.
23. Verebey K, Volavka J, Mule SJ, Resnick RB(1976) Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clinical Pharmacological Therapy, 20(3):315-28.